- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
Country-wise biosimilar pipelines number in development worldwide 2017
Premium statistics
Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
Country-wise biosimilar pipelines number in development worldwide 2017
Number of biosimilars in development worldwide as of October 2017, by country
by Matej Mikulic,
last edited
Jul 22, 2019
This statistic displays the Number of biosimilars in development worldwide as of October 2017, by country. China had 269 biosimilars in development, which was the largest number, followed by India with 257 biosimilars in development.
Number of biosimilars in development worldwide as of October 2017, by country
| Number of biosimilars | |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| Number of biosimilars | |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
Exclusive content
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
by Matej Mikulic,
last edited
Jul 22, 2019
This statistic displays the Number of biosimilars in development worldwide as of October 2017, by country. China had 269 biosimilars in development, which was the largest number, followed by India with 257 biosimilars in development.
- Show sources information
- Show publisher information
- Release date
- 2018
- Region
- Worldwide
- Survey time period
- as of October 2017
Source
- Show sources information
- Show publisher information
- Release date
- 2018
More information
- Region
- Worldwide
- Survey time period
- as of October 2017
Other statistics on the topic
+Pharmaceutical Products & Market
Pharmaceutical market: worldwide revenue 2001-2018
+Pharmaceutical Products & Market
Revenues of leading global generics manufacturers 2018
+Pharmaceutical Products & Market
U.S. brand and generic prescription drug revenue 2005-2018
+Pharmaceutical Products & Market
Pfizer's revenue by segment 2014-2018
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Related Studies: Available to Download in PDF or PPTX Format
All Information
in one Presentation
Generics and biosimilars
- 82 page/s
- English
- pptx
- Detailed references
Everything On "Generics and biosimilars" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.
Other Reports & Dossiers
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.Marlene Greenfield
Vice President, Hearst Magazines
Statistics on "Generics and biosimilars"
- Global overview
The most important statistics
- Revenue of the worldwide pharmaceutical market from 2001 to 2018 (in billion U.S. dollars)Pharmaceutical market: worldwide revenue 2001-2018
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)Total worldwide generic prescription drug revenue 2010-2024
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024Global generic prescription drug revenues as share of prescribed revenue 2010-2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*Patent expiration risks for total worldwide prescription drug revenue 2010-2024
- Top companies
The most important statistics
- Top generics manufacturers based on revenue in 2018 (in billion U.S. dollars)*Revenues of leading global generics manufacturers 2018
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)Teva Pharmaceutical Industries' generic revenues by region 2016-2018
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)Novartis revenue 2014-2018 by segment
- Pfizer's revenue in 2014 and 2018, by segment (in million U.S. dollars)*Pfizer's revenue by segment 2014-2018
- U.S. market
The most important statistics
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2018 (in billion U.S. dollars)*Brand and generic prescription medication revenue in the U.S. 2006-2018
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018U.S. brand and generic prescription drug revenue 2005-2018
- Change in branded and generic medication spending in the United States from 2013 to 2018 (in billion U.S. dollars)*Spending change on branded and generic medicines in the U.S. 2013-2018
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*Unbranded generics revenue top corporations in U.S. 2016-2017
- Top companies based on unbranded generics U.S. market share during 2016-2017*Unbranded generics market share top corporations in U.S. 2016-2017
- Top 20 U.S. pharma products by dispensed prescriptions in 2018 (in millions)Top U.S. pharma products by prescriptions 2018
- Patent expiration
The most important statistics
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)Projected sales at risk due to patent expiry 2009-2022
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018Top pharma companies by sales loss due to patent loss until 2018
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*Forecast of new brand and LOE impact on growth of developed pharma markets 2018-2022
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*Top branded biologic drugs in the U.S. that will go generic by 2028
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014Time from brand drug launch to generic patent challenges U.S. 1995-2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)Comparison of pre-expiry and generic price for drugs U.S. 2015
- Savings
The most important statistics
- Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)Savings through generic drug usage in the U.S. 2008-2018
- Top generic drugs based on savings in the United States in 2018 (in million U.S. dollars)Total savings of top generic drugs in U.S. 2018
- Cost savings through generics in the United States in 2018, by select therapeutic area (in billion U.S. dollars)*Saving of U.S. costs through generic pharmaceuticals by select therapy 2018
- Savings through generic drug usage in the United States in 2018, by age group (in billion U.S. dollars)Savings through generic drug usage in the U.S., by age group 2018
- Savings through generic drug usage in the United States in 2018, by payer (in billion U.S. dollars)Savings through generic drug usage in the U.S., by payer 2018
- Percentage of savings through generic drug usage in the United States in 2018, by payerPercentage savings through generic drug usage in the U.S. by payer 2018
- Percentage of savings through generic drug usage in the United States in 2018, by age groupSavings through generic drug usage in the U.S., by age group share 2018
- Biosimilars
The most important statistics
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Number of biosimilars in development worldwide as of October 2017, by country Country-wise biosimilar pipelines number in development worldwide 2017
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)Reduction in U.S. direct spending on originator biologics as of 2018
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Example of physician office payment for biosimilars in Medicare Part B as of 2019 (in U.S. dollars)*Physician office payment for biosimilars in Medicare Part B in 2019
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Orphan vs. non-orphan pipeline sales forecast worldwide 2019-2024
- New pharmaceutical drugs in R&D pipelines in South Korea 2014, by therapeutic area
- Global pharmaceutical pipeline by therapy area 2013-2017
- Type 2 diabetes clinical pipeline in the U.S. in 2018, by type and phase
- Obesity drugs clinical pipeline U.S. 2018, by type and phase
- U.S. addiction medication clinical trials in 2018, by phase and indication
- Drugs in R&D pipeline worldwide 2018 vs. 2019, by phase of development
- Top promising pipeline drugs for chronic hepatitis B, 2014, by sales
- Distribution of U.S. clinical and phase III pipeline 2013 by indication
- U.S. hotel rooms in the development pipeline December 2018, by chain scale
- Asia's pipeline of coal power plants globally 2015, by select country
- Share of infrastructure project value in the pipeline in the GCC by country 2016
- U.S. pipeline transportation gross output 1998-2017
- Share of infrastructure project value in the pipeline in the GCC by sector 2016
- Share of the global steel pipeline coatings market value by application 2015
- Deepwater pipeline installation worldwide length by region 2010-2017
- U.S. opinion by political group on government approval of Keystone XL pipeline 2012
- Distribution of Alberta's pipeline transportation by substance 2016
- Top oil gas operators worldwide by deepwater pipeline installation 2011-2015
- Producer price index of noncurrent-carrying wiring devices 2005-2016
Statistics on "Generics and biosimilars"
- Pharmaceutical market: worldwide revenue 2001-2018
- Total worldwide generic prescription drug revenue 2010-2024
- Global generic prescription drug revenues as share of prescribed revenue 2010-2024
- Patent expiration risks for total worldwide prescription drug revenue 2010-2024
- Revenues of leading global generics manufacturers 2018
- Teva Pharmaceutical Industries' generic revenues by region 2016-2018
- Novartis revenue 2014-2018 by segment
- Pfizer's revenue by segment 2014-2018
- Brand and generic prescription medication revenue in the U.S. 2006-2018
- U.S. brand and generic prescription drug revenue 2005-2018
- Spending change on branded and generic medicines in the U.S. 2013-2018
- Unbranded generics revenue top corporations in U.S. 2016-2017
- Unbranded generics market share top corporations in U.S. 2016-2017
- Top U.S. pharma products by prescriptions 2018
- Projected sales at risk due to patent expiry 2009-2022
- Top pharma companies by sales loss due to patent loss until 2018
- Forecast of new brand and LOE impact on growth of developed pharma markets 2018-2022
- Top branded biologic drugs in the U.S. that will go generic by 2028
- Time from brand drug launch to generic patent challenges U.S. 1995-2014
- Comparison of pre-expiry and generic price for drugs U.S. 2015
- Savings through generic drug usage in the U.S. 2008-2018
- Total savings of top generic drugs in U.S. 2018
- Saving of U.S. costs through generic pharmaceuticals by select therapy 2018
- Savings through generic drug usage in the U.S., by age group 2018
- Savings through generic drug usage in the U.S., by payer 2018
- Percentage savings through generic drug usage in the U.S. by payer 2018
- Savings through generic drug usage in the U.S., by age group share 2018
- Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Country-wise biosimilar pipelines number in development worldwide 2017
- Reduction in U.S. direct spending on originator biologics as of 2018
- Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2017
- Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
- Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Physician office payment for biosimilars in Medicare Part B in 2019
- Orphan vs. non-orphan pipeline sales forecast worldwide 2019-2024
- New pharmaceutical drugs in R&D pipelines in South Korea 2014, by therapeutic area
- Global pharmaceutical pipeline by therapy area 2013-2017
- Type 2 diabetes clinical pipeline in the U.S. in 2018, by type and phase
- Obesity drugs clinical pipeline U.S. 2018, by type and phase
- U.S. addiction medication clinical trials in 2018, by phase and indication
- Drugs in R&D pipeline worldwide 2018 vs. 2019, by phase of development
- Top promising pipeline drugs for chronic hepatitis B, 2014, by sales
- Distribution of U.S. clinical and phase III pipeline 2013 by indication
- U.S. hotel rooms in the development pipeline December 2018, by chain scale
- Asia's pipeline of coal power plants globally 2015, by select country
- Share of infrastructure project value in the pipeline in the GCC by country 2016
- U.S. pipeline transportation gross output 1998-2017
- Share of infrastructure project value in the pipeline in the GCC by sector 2016
- Share of the global steel pipeline coatings market value by application 2015
- Deepwater pipeline installation worldwide length by region 2010-2017
- U.S. opinion by political group on government approval of Keystone XL pipeline 2012
- Distribution of Alberta's pipeline transportation by substance 2016
- Top oil gas operators worldwide by deepwater pipeline installation 2011-2015
- Producer price index of noncurrent-carrying wiring devices 2005-2016
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Save statistic in .XLS format
You can only download this statistic as a Premium user.
Save statistic in .PNG format
You can only download this statistic as a Premium user.
Save statistic in .PDF format
You can only download this statistic as a Premium user.
Show source references
As a Premium user you get access to the detailed source references and background information about this statistic.
Show details about this statistic
As a Premium user you get access to background information and details about the release of this statistic.
Bookmark statistics
As soon as this statistic is updated, you will immediately be notified via e-mail.
Change statistics options
You need at least a Premium Account to use this feature.
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.